Pre-made Yttrium (90Y) Tacatuzumab Tetraxetan benchmark antibody (Radiolabelled antibody, anti-AFP therapeutic antibody, Anti-AFPD/FETA/HPAFP Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Yttrium (90Y) Tacatuzumab Tetraxetan benchmark antibody (Radiolabelled antibody, anti-AFP therapeutic antibody, Anti-AFPD/FETA/HPAFP Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Yttrium (9Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-9,[2] a radioisotope which destroys the tumour cells.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1053-1mg	1mg	3090
GMP-Bios-INN-1053-10mg	10mg	Inquiry
GMP-Bios-INN-1053-100mg	100mg	Inquiry
GMP-Bios-INN-1053-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Yttrium (90Y) Tacatuzumab Tetraxetan Biosimilar, Radiolabelled Antibody, Anti-Afp Antibody: Anti-AFPD/FETA/HPAFP therapeutic antibody
INN Name	Yttrium (90Y) Tacatuzumab Tetraxetan
Target	AFP
Format	Radiolabelled antibody
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Immunomedics Inc. (Morris Plains NJ USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0